ponatinib
Selected indexed studies
- Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. (JAMA, 2024) [PMID:38722621]
- Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. (Lancet Haematol, 2023) [PMID:36402146]
- Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation. (Circ Res, 2023) [PMID:36625265]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. (2024) pubmed
- Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. (2023) pubmed
- Ponatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation. (2023) pubmed
- Integrated Stress Response Potentiates Ponatinib-Induced Cardiotoxicity. (2024) pubmed
- Ponatinib: A comprehensive drug profile. (2024) pubmed
- Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. (2024) pubmed
- Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. (2023) pubmed
- Ponatinib-review of historical development, current status, and future research. (2024) pubmed
- Ponatinib in the treatment of acute lymphoblastic leukemia. (2025) pubmed
- Ponatinib: An update on its drug targets, therapeutic potential and safety. (2023) pubmed